Navigation Links
Takeda Responds to FDA Advisory Committee Recommendation
Date:7/14/2010

nd other public health matters. The FDA frequently convenes its panel of outside experts to provide guidance and recommendations; however, the recommendations of the committee are not a final decision. The FDA will evaluate the committee's decision and their final recommendations will follow.

Takeda remains committed to ACTOS and to the millions of people living with type 2 diabetes. Takeda is the inventor and developer of ACTOS, which was launched commercially in the U.S. in 1999. ACTOS, as labeled, is an effective and appropriate treatment option for many people living with type 2 diabetes. Since its launch, more than 100 million ACTOS family prescriptions have been written, covering more than 10 million patients. In clinical trials using ACTOS in monotherapy, the most common adverse events (greater than or equal to 5%) were upper respiratory tract infection, headache, sinusitis, myalgia, tooth disorder, aggravated diabetes mellitus, and pharyngitis.

About ACTOS® (pioglitazone HCl) Indications and Usage

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS has been studied as a monotherapy and in combination with sulfonylurea, metformin, or insulin.

Important Safety Information

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause new, or worsen, heart failure. Patients should talk to their doctor immediately if they experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness.

ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis.

ACTOS may cause low blood sugar when taken in combination with insulin
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BEDFORD, Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the ... City , New York on ... Interested parties are invited to listen to the live ... Hologic,s website at www.hologic.com/investors-overview . An archive of the ...
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire/ ... announced the submission of a Marketing Authorization ... (EMA) via the centralized procedure for talimogene ... adults with melanoma that is regionally or ... immunotherapy administered as an intralesional injection that ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
... LAKES, N.J. , May 11 Nearly ... (LABAs) alone, and not in combination with other asthma ... and Drug Administration (FDA) on the risk of worsening ... according to a new study from the Medco ...
... May 11 Ethicon Endo-Surgery ... of surgical devices, the HARMONIC FOCUS® Long Curved Shears, ... that require deep access. The HARMONIC FOCUS® Long Curved ... using precise ultrasonic energy that minimizes thermal damage to ...
Cached Medicine Technology:Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 2Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 3Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 4Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 5Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access 2
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... Dallas, TX (PRWEB) September 02, 2014 On ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... from 8:00 am to 1:00 pm. , “Since 2007, ...
(Date:9/2/2014)... 2014 Durable Medical Goods manufacture ... leasing and financing company LeaseQ, Inc. to help customers ... Since late 2012, LeaseQ’s breakthrough finance shopping platform has ... they need to run their business. , Said ... enable the ThermoTek sales team to provide customers faster ...
(Date:9/2/2014)... 02, 2014 The American Healthcare Documentation ... Free-Tuition Guarantee for its ICD-10 Medical Coding Bridge Program. ... highest level of confidence to students who are seeking ... but are faced with the uncertainty brought on by ... ICD-10 until October 1st, 2015. , AHDPG’s Free-Tuition Guarantee ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3
... January is Thyroid Awareness Month , JACKSONVILLE, Fla. , ... and feel our best. Yet many never realize that one of ... just below the neck.   , The thyroid is a small, ... affect the function of many of the body,s organs including the ...
... 2010 - Chronic and severely stressful situations, like those ... associated with smaller volumes in "stress sensitive" brain regions, ... and the hippocampus, a brain region involved in memory ... Biological Psychiatry , suggests that chronic insomnia may ...
... 27, 2010) Researchers at Tufts University School of Medicine ... have developed a new tool for gene therapy that significantly ... other carriers and DNA alone, according to a study published ... Medicine . The tool, a peptide called PEG-POD, provides a ...
... to delay lactation in new moms, researchers find , ... class of antidepressants can cause delayed lactation in new ... order to breast-feed their babies, a new study says. ... reuptake inhibitors (SSRIs), which include such drugs as Prozac ...
... ... ... recognition of cervical cancer awareness month, Debra Macki , one of the industry’s most ... of this preventable cancer. The palette includes three shades that represent the three tools women ...
... ... Payment Platform for Utah’s Answer to Health Care Reform , ... Salt Lake City, UT (Vocus) January 27, ... by the State of Utah to provide payment-processing solutions and HSA administration for the ...
Cached Medicine News:Health News:Unlocking the Secrets to a Healthier Body 2Health News:Unlocking the Secrets to a Healthier Body 3Health News:Losing sleep, losing brain? 2Health News:Researchers develop new tool for gene delivery 2Health News:Antidepressants May Complicate Breast-Feeding 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 3Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: